The full meeting summary from the FDA Rare Disease Patient-led Listening Session on CMT-SORD, held on 4 August 2026. Fifty-two people took part, including representatives from four FDA centers, the NIH, and the Reagan-Udall Foundation. Read it below, or download the PDF.
Changes how this site looks for you, and are saved on this device.
We use cookies to see how the site is used (analytics) and to power embedded videos and podcasts. Analytics stay off until you say yes. See our privacy policy.
Be the first to know
Research moves fast. Add your number and we will text you the things that matter most: new treatment news, trial openings, and ways to take part before they fill up.